Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: TROP2 methylation and expression in tamoxifen-resistant breast cancer

Fig. 4

TACSTD2 methylation and TROP2 staining in primary and recurrent breast tumors. Mean beta values for each of three CpGs in the promoter region of TACSTD2 (MAPINFO numbers 59043370, 59043280 and 59043255), which were previously identified as hypermethylated in TMX2-28, are shown for 6 sets of ERpos primary to ERneg recurrent breast cancers (a), and 12 sets of ERpos primary to ERpos recurrent breast cancers (d). There was no significant change in methylation between primary and recurrent tumors when the recurrent tumor was ERneg (a: p = 0.25) or ERpos (d: p = 0.27). Membrane TROP2 and Ki67 expression, determined by IHC, for same sets of primary and recurrent breast tumors shown in (b, e) and (c, f). There was no significant difference in membrane TROP2 expression between primary and recurrent tumor when the recurrent tumor was ERneg (b: p = 0.891) and or ERpos (e: p = 0.067; n = 10 because staining failed in two recurrent tumors). There was no significant difference in Ki67 expression between primary and recurrent tumor when the recurrent tumor was ERneg (c: p = 0.182) or ERpos (f: p = 0.463)

Back to article page